Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adenosine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 known ✓ | P47900 | 10/20 | 0.83 |
| ▸ | P2RY2 known ✓ | P41231 | 3/20 | 0.83 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.73 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.73 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.83 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.83 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.83 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.77 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.77 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.77 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.77 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.73 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.73 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL29573857 | 1.00 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL29663097 | 1.00 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL29392565 | 0.99 | P2RY1 (0.81) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL29636841 | 0.99 | P2RY1 (0.81) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL19947525 | 0.98 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL31158049 | 0.95 | P2RY1 (0.87) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL30929365 | 0.95 | P2RY1 (0.87) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL5498270 | 0.95 | P2RY1 (0.87) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL29467395 | 0.95 | P2RY1 (0.89) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL1496208 | 0.95 | P2RY1 (0.89) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406729-B1 | METHOD FOR ENZYMATIC PREPARATION OF FLUDARABINE PHOSPHATE | ZHEJIANG HISUN PHARM CO LTD (CN) | 2025-09-17 | — | — | EP | claimed |
| US-12350388-B2 | Methods for measuring and quantifying surface cleanability of articles | B/E AEROSPACE, INC. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4148420-B1 | METHODS FOR MEASURING AND QUANTIFYING SURFACE CLEANABILITY OF ARTICLES | BE AEROSPACE INC (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119639715-A | Nicotinamide mononucleotide adenyltransferase mutant and application thereof | 浙江工业大学 | 2025-03-18 | — | — | CN | claimed |
| WO-2024178428-A9 | SHELF STABLE ORGANIC NUCLEOTIDE COMPOSITIONS AND METHODS OF MANUFACTURING THE SAME | Glanbia Nutritionals, Inc. (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2024178428-A1 | SHELF STABLE ORGANIC NUCLEOTIDE COMPOSITIONS AND METHODS OF MANUFACTURING THE SAME | Glanbia Nutritionals, Inc. (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240285541-A1 | SHELF STABLE ORGANIC NUCLEOTIDE COMPOSITIONS AND METHODS OF MANUFACTURING THE SAME | Glanbia Nutritionals, Inc. (US) | 2024-08-29 | — | — | US | claimed |
| CN-117467718-A | Method for preparing pyridoxal 5' -phosphate | 湖北远大生物技术有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116064466-A | High-density fermentation process of nicotinamide riboside kinase and application of nicotinamide riboside kinase in NMN production | 江西海文生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2023040205-A1 | METHOD FOR EFFICIENTLY PREPARING NICOTINAMIDE MONONUCLEOTIDE AND FUSION PROTEIN | 湖北远大生命科学与技术有限责任公司 | 2023-03-23 | — | — | WO | claimed |
| US-20230077611-A1 | METHODS FOR MEASURING AND QUANTIFYING SURFACE CLEANABILITY OF ARTICLES | B/E AEROSPACE, INC. | 2023-03-16 | — | — | US | claimed |
| EP-4148420-A1 | METHODS FOR MEASURING AND QUANTIFYING SURFACE CLEANABILITY OF ARTICLES | B/E Aerospace, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| CN-115637262-A | Method for efficiently preparing nicotinamide mononucleotide and fusion protein | 湖北远大生命科学与技术有限责任公司 | 2023-01-24 | — | — | CN | claimed |
| EP-3962493-A2 | METHODS OF MODULATING IMMUNE ACTIVITY/LEVEL OF IRF OR STING OR OF TREATING CANCER, COMPRISING THE ADMINISTRATION OF A STING MODULATOR AND/OR PURINERGIC RECEPTOR MODULATOR OR POSTCELLULAR SIGNALING FACTOR | Flagship Pioneering Innovations V, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4717695-A1 | CRYSTAL FORM AND SALT FORM OF FIVE- AND SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE | Hangzhou Polymed Biopharmaceuticals, Inc. (CN) | 2026-04-01 | — | — | EP | disclosed |
| CN-103110602-A | Disodium adenosine triphosphate troche medical composition | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2013-05-22 | — | — | CN | disclosed |
| CN-102449168-A | Genotoxicity testing | GENTRONIX LTD | 2012-05-09 | — | — | CN | disclosed |
| US-20120035079-A1 | GENOTOXICITY TESTING | GENTRONIX LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | P2RY1 2863/4885P2RY2 3576/4885ADORA1 1318/4885 |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | MAP2K4, MAP2K1, MAP2K3 | P2RY1 2707/4885P2RY2 3047/4885ADORA1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.